CORRECTION article

Front. Oncol., 04 August 2022

Sec. Pharmacology of Anti-Cancer Drugs

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.995352

Corrigendum: The risk of heart disease-related death among anaplastic astrocytoma patients after chemotherapy: A SEER population-based analysis

  • 1. Department of Neurosurgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China

  • 2. Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, China

Article metrics

View details

1,3k

Views

746

Downloads

In the published article, there was an error in affiliation 1. Instead of “1Department of Neurosurgery, School of Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China”, it should be “Department of Neurosurgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China” as above.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

anaplastic astrocytoma, chemotherapy, SEER, heart disease-related death, cardio-oncology

Citation

Lin Q, Bao J-H, Xue F, Qin J-J, Chen Z, Chen Z-R, Li C, Yan Y-X, Fu J, Shen Z-L and Chen X-Z (2022) Corrigendum: The risk of heart disease-related death among anaplastic astrocytoma patients after chemotherapy: A SEER population-based analysis. Front. Oncol. 12:995352. doi: 10.3389/fonc.2022.995352

Received

15 July 2022

Accepted

19 July 2022

Published

04 August 2022

Approved by

Frontiers Editorial Office, Media SA, Switzerland

Volume

12 - 2022

Updates

Copyright

*Correspondence: Xian-Zhen Chen, ; Zhao-Li Shen, ; Jin Fu,

† These authors have contributed equally to this work and share first authorship

‡ These authors have contributed equally to this work

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics